This activity is intended for hematology/oncology (heme/onc) physicians, physician associates (PAs), nurse practitioners (NPs), nurses, pharmacists, residents, fellows, and other healthcare professionals (HCPs) who manage patients with myeloproliferative neoplasms (MPN).

After completing this activity, the participant should be better able to: 

• Integrate validated prognostic models, molecular biomarkers, and symptom assessment tools into initial assessment and treatment plan for patients with myeloproliferative neoplasms (MPNs)
• Evaluate current and emerging therapeutic options for appropriate integration into the MPN care setting
• Implement a multifaceted approach to the management of patients with MPN, including symptom relief complication prevention, appropriate therapy selection, and adverse event mitigation

• Welcome & Introduction
• Optimizing Guideline-Directed, Risk-Adapted Therapy in PV, ET, and MF
• Evolving Treatment Paradigms in MPNs: From Established to Novel Therapies
• Comprehensive Care in MPNs: Symptom Relief, Complication Prevention and Therapeutic Decision-Making
• Call to Action and Q&A

This activity is provided by MLI

Accreditation, Support and Credit 

In support of improving patient care, Medical Learning Institute Inc is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physician Continuing Medical Education 

Medical Learning Institute Inc (MLI) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

MOC Statement

 Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

For Physicians requesting MOC credit, the post-test and evaluation are required in their entirety as well as your ABIM ID number, DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC credit.

Notice to Diplomates: MLI will report any claimed MOC/Lifelong Learning points to the appropriate Board within 4 weeks of completing the activity. Please ensure that you have provided your Board ID number and MMDD of birth.

For Canadian Physicians

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

EBAH

 Medical Learning Institute Inc is an accredited CME-CPD provider by the European Board for Accreditation in
Hematology (EBAH).

This educational activity has been submitted to EBAH for review. Final EBAH CME-CPD credits information will be provided to learners prior to the live activity.

PA

Medical Learning Institute Inc has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

Pharmacy

Medical Learning Institute Inc designates this application-based continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.
UAN: JA0007322-0000-26-021-L01-P

For Pharmacists, MLI will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, view your participation record at the NABP website: https://nabp.pharmacy/

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour and 0.33 contact hour in the area of pharmacology.

ILNA

This program content has been submitted to the Oncology Nursing Certification Corporation (ONCC) for review. Final ILNA points and coding information will be provided to learners prior to the live activity.

Support Statement 

This activity is supported by educational grants from Bristol Myers Squibb, Karyopharm Therapeutics, and PharmaEssentia USA Corporation

Medical Learning Institute Inc is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.

Faculty Disclosures

Planner/Presenter

Aaron T. Gerds, MD, MS, has a financial interest/relationship or affiliation in the form of:

Advisory Board: AN2 Therapeutics, Bristol Myers Squibb, Disc Medicine, Geron, GlaxoSmithKline, Incyte, Karyopharm, Keros, Merck, Novartis, PharmaEssentia, Takeda, V6

Planner/Presenter

John Mascarenhas, MD, has a financial interest/relationship or affiliation in the form of:

Consultant/Advisor: AbbVie, Blueprint Medicines, Bristol Myers Squibb, Cogent, Disc Medicine, Galecto, Geron, GlaxoSmithKline, Incyte, Italfarmaco Spa, Karyopharm, Merck, Novartis, Opna, PharmaEssentia, Roche, Sobi

Research Funding/Support: AbbVie, Ajax, Bristol Myers Squibb, Disc Medicine, Geron, Incyte, Italfarmaco Spa, Kartos, Karyopharm, MorphoSys, Novartis, PharmaEssentia, Sobi

All of the relevant financial relationships of individuals for this activity have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from Medical Learning Institute Inc, the accredited provider, do not have any relevant financial relationships to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity, however, registration is required. In order to receive credit, learners must participate in the entire CE activity, complete the activity evaluation form and your certificate of credit will be generated. You will receive your certificate from Medical Learning Institute Inc.

For information on applicability and acceptance of continuing education credit for this CE activity, please consult your professional licensing board.

If you have questions regarding your certificate, please contact MLI at mvu@mlieducation.org.

About This Activity

Medical Learning Institute Inc is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute Inc or any of its partners, providers, and/or supporters.

Copyright © 2026 Medical Learning Institute Inc. All Rights Reserved.